|
Synonyms: IZCARGO® | JR-141 | JR141
pabinafusp alfa is an approved drug (Japan (2021))
Compound class:
Antibody
Comment: Pabinafusp (JR-141) is a fusion protein of the Fab domains of an anti-transferrin receptor monoclonal and the enzyme iduronate 2-sulfatase (IDS; P22304) [5], an enzyme that is deficient in patients with the lysosomal storage disease mucopolysaccharidosis type II (MPS II; Hunter syndrome) [1-2]. It is an intravenously administered enzyme replacement therapy. The anti-transferrin receptor component facilitates receptor-mediated movement of the fused enzyme across the blood-brain barrier [4].
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (Japan (2021)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10995 | pabinafusp alfa |
| Synonyms |
| IZCARGO® | JR-141 | JR141 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 914 |
| Other databases | |
| GtoPdb PubChem SID | 458923807 |
| Search PubMed clinical trials | pabinafusp alfa |
| Search PubMed titles | pabinafusp alfa |
| Search PubMed titles/abstracts | pabinafusp alfa |
